Investing in volatile times: Alphaville’s top tips

You may have missed this amid all the talk of heat and drought and the cost of living crisis, but equity markets in Europe and the US have enjoyed a remarkable summer bounce.

Having plummeted for much of the first half of the year, Wall Street’s S&P 500 has climbed 12 per cent in a month, Europe’s Stoxx 600 has risen 4 per cent over the same period and the MSCI All-Country World Index is up by just under a tenth. After a dismal start to 2022, technology stocks are once again performing well. As Harvest Volatility’s Mike Zigmont, says: “Bulls like to party.”

But recent investor optimism rests on shaky foundations. Russia’s invasion of Ukraine looks set to trigger recessions in countries heavily dependent on the aggressor’s oil and gas. Meanwhile, consumer sentiment is dire despite low rates of unemployment, and across much of the west inflation is as hot as it’s been in 40-odd years.

The US Federal Reserve and other central banks are talking tough as a result. Bond markets — in the US at least — have turned decidedly dovish, with prices rising and yields dropping again. Some investors clearly think tighter monetary policy is set to trigger economic downturns, which will eventually pave the way for lower rates.

Elsewhere, the cryptocurrency market is in disarray, China’s economy is slowing and a strengthening dollar has left lower-income countries facing soaring debt obligations. The spectre of stagflation looms large across the board.

So where to put your money? A particularly tricky question for British investors, with the government in disarray pending the end of the Tories’ leadership election.

Going out on a limb with investment advice in the illiquid dog days of August is risky business. “The one thing that we can say with some confidence is

Read More

Moderna CFO out soon after two times in the job as previous employer Dentsply discloses probe of economical reporting

Moderna Inc. amazed traders Wednesday with the information that its chief fiscal officer has departed the enterprise just two days right after using up the place, following the disclosure of an inside probe into money reporting at his former employer.

Jorge Gomez, who grew to become Moderna’s CFO on Monday, has remaining the biotech following Dentsply Sirona Inc.
XRAY,
+1.00%
disclosed the probe. Right before becoming a member of Moderna, Gomez had been CFO of Dentsply considering the fact that 2019.

The maker of dental merchandise and know-how stated it was late filing its 10-Q quarterly earnings type with the Securities and Exchange for the reason that of the investigation.

“The investigation is ongoing, and the corporation are not able to predict the length or result of the investigation,” reported the filing. “As a consequence, the corporation has not yet finalized its fiscal statements or its assessment of the affect of the investigation on its historic financial statements or for the money statements for the a few months finished March 31, 2022, and is as a result not able to file the Type 10-Q on a well timed basis.”

In a independent filing, the company presented more detail, stating that its audit and finance committees are investigating allegations about specified economical issues submitted by previous and latest personnel. The investigation is focused on the company’s use of incentives to provide items to distributors in the 3rd and fourth quarters of 2021 and “whether those people incentives have been correctly accounted for and the influence of people gross sales was adequately disclosed in the company’s periodic experiences filed with the SEC.”

See also: Drug organizations are creating an accounting improve just after the SEC cracked down on Biogen

The exercise, acknowledged as “channel-stuffing,” is a misleading a single employed to inflate

Read More

Carvana bets on $2.2B ADESA U.S. acquisition to broaden its access, minimize transport times

On the net utilised-motor vehicle retailer Carvana, pressed in current months to develop its auto reconditioning capability, claimed Thursday it ideas to acquire the ADESA U.S. actual physical wholesale auction business enterprise from KAR Worldwide Inc. for $2.2 billion in cash.

The transaction would give Carvana special use of the ADESA.com marketplace in the U.S., in addition all auction gross sales, operations and workforce at ADESA’s 56 vehicle logistics centers in the country. It also would support expand the on the net retailer’s client arrive at and boost its manufacturing capability by an believed 2 million cars for every calendar year, Carvana CEO Ernie Garcia explained.

The offer, which is predicted to near in the second quarter of 2022, “substantially improves” the span of Carvana’s logistics network, Garcia claimed late Thursday on a conference phone just after the retailer introduced a $182 million internet loss for the fourth quarter even as quarterly and yearly profits soared.

“We will go from at present acquiring inspection facilities in 200 miles of 56 percent of the U.S. populace to inevitably becoming in just 200 miles of 94 per cent of the U.S. population,” Garcia mentioned. “Demonstrating the high-quality of these spots, we will transfer from currently being in 50 miles of 16 per cent of the U.S. inhabitants to remaining within just 50 miles of 58 % of the population.”

That will slash shipping and delivery situations to Carvana customers, Garcia explained.

Carvana opened its 15th inspection and reconditioning heart at the commencing of 2022, which introduced its full generation capacity to 880,000 autos, Garcia stated. Creation for the retailer usually means obtaining utilized automobiles and vans sale-completely ready: receiving, inspecting and reconditioning them.

The corporation designs to open 6 extra centers by the finish of the year. 5 will open

Read More

Artificial Intelligence Comes of Age in the Fight Against Ca… : Oncology Times

Artificial Intelligence:

Artificial Intelligence

The SAS Virtual Health Artificial Intelligence (AI) Summit on Cancer Research1 was held this year to share best practices, ongoing challenges, and future opportunities for advancing cancer treatment through analytics. Innovations in applying computer vision to medical images and using machine learning (ML) to build predictive models may help clinicians assess therapeutic results more efficiently, thereby enhancing personalized approaches to cancer treatment.

AI is the application of digital devices and computers to enhance human intelligence.2 In this article, we focus on the use of AI to develop ML and deep learning (DL) models. Whereas ML is the subfield of AI using mathematical and statistical approaches to derive models from data, DL is a specific class of ML that leverages complex networks in its learning process (Figure 1).3

F2-1
Figure 1.:

Relationship Among AI, ML, and DL

Four Key Themes from the Summit

1. Applying Response Evaluation Criteria for Solid Tumors (RECIST 1.1) criteria to solid tumors involves measuring the largest diameter of a tumor, but tumor volume and morphology give a more comprehensive assessment of treatment response,4,5 so there is an opportunity to improve RECIST 1.1 with AI, ML, and DL.6 AI can determine volumetric changes in the three-dimensional morphology of cancers that are not simple spherical or elliptical structures, while eliminating subjectivity and observer variability7-10 and reducing time assessing tumor response. The combination of clinical data features, such as AI-assisted interpretation of test reports and longitudinal patient level data, can train DL and ML models to improve the diagnostic accuracy of radiographic studies.11,12

AI may also be used to give objective histopathological results, as in a recent study of patients with pancreatic cancer. Digitized, segmented images of tumors were used to segment residual tumor burden after

Read More